Pronota Strengthens Management Team: Former VP Corporate Development Genzyme joins as CBO

Ghent, Belgium, 16 March 2012, Pronota NV, the devel­oper of first-in-class diag­nos­tics for early detec­tion of life-threatening con­di­tions, has appointed Carol Greve-Philips as Chief Business Officer and Els Hubloux as Chief Financial Officer.
Pronota has an inno­v­a­tive tech­nol­ogy for iden­ti­fy­ing low quan­ti­ties of pro­tein cir­cu­lat­ing in the blood, enabling ear­lier or bet­ter diag­no­sis of life threat­en­ing dis­eases. Pronota has lead pro­grams in preeclamp­sia, ovar­ian can­cer and sep­sis. Pronota is com­mit­ted to mak­ing a dif­fer­ence in diag­no­sis and per­son­al­ized health­care through use of its high value, non-invasive and pro­pri­etary pro­tein diag­nos­tic prod­ucts.
Katleen Verleysen, CEO of Pronota, said: “I’m delighted to have Carol and Els join Pronota, where their sub­stan­tial busi­ness devel­op­ment and invest­ment expe­ri­ence will greatly enhance Pronota resources to drive our prod­ucts through clin­i­cal devel­op­ment to com­mer­cial­iza­tion. With the team in place, I look for­ward to the estab­lish­ment of new part­ner­ships.”
Carol Greve-Philips is an expe­ri­enced biotech­nol­ogy pro­fes­sional with over 20 years of busi­nesS devel­op­ment skills. She joins Pronota from Genzyme Corporation, where she was Vice President of Corporate Development, respon­si­ble for build­ing col­lab­o­ra­tions with indus­try part­ners that brought novel prod­ucts to the Personalized Genetic Health busi­ness. In addi­tion, Carol led suc­cess­ful out­li­cens­ing trans­ac­tions for non-core assets. Carol has also held roles in direct sales, sales man­age­ment and mar­ket­ing for Amersham Corporation, Chemsyn Science Laboratories, Watson Laboratories and Toxikon Corporation. Carol has a BSc in Zoology and Chemistry from the University of Massachusetts at Amherst.Commenting on her appoint­ment, Carol said: “I’m excited to be able to use my exten­sive busi­ness expe­ri­ence gained at Genzyme to sup­port Pronota’s devel­op­ment of pro­pri­etary inno­v­a­tive diag­nos­tics focused on improv­ing qual­ity of care for patients.”
Els Hubloux is an MBA qual­i­fied invest­ment pro­fes­sional, orig­i­nally trained as a chem­i­cal engi­neer, and joins Pronota from Capricorn Venture Partners. Her career encom­passes over 16 years of expe­ri­ence in clin­i­cal research and devel­op­ment, equity research and ven­ture cap­i­tal invest­ment. Els has been involved in numer­ous trans­ac­tions span­ning pri­vate and pub­lic offer­ings as well as M&As. Els has both a Chemical Engineering Degree and an MBA from the University of Brussels.
Commenting on her appoint­ment, Els said: “Having secured sub­stan­tial fund­ing in related fields, I am delighted to be in a posi­tion to help grow Pronota’s busi­ness, work­ing with our solid investor base, and net­work of renowned key opin­ion lead­ers, to sup­port the devel­op­ment of our life-saving pro­grams in mater­nal health, ovar­ian can­cer, and sep­sis.”